Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galinpepimut-S + Pembrolizumab in Advanced Cancers
NCT03761914Phase 2Completed
- Sponsor
- SELLAS Life Sciences Group, Inc.
- Start
- Sep 2019
- Primary completion
- Jul 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of galinpepimut-s in colorectal cancer (CRC), ovarian cancer, small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), acute myeloid leukemia (AML), sponsored by SELLAS Life Sciences Group, Inc.. Started Sep 2019; status: completed.
02
Drugs
galinpepimut-s
03
Conditions
colorectal cancer (CRC)ovarian cancersmall cell lung cancer (SCLC)triple-negative breast cancer (TNBC)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03761914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03761914.